-
Mashup Score: 0Korean researchers develop AI to predict adverse drug reactions with Pfizer's Paxlovid - 1 year(s) ago
The antiviral medication was found to interact with over 2,000 prescription drugs.
Source: MobiHealthNewsCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1FDA Panel Backs Full Approval of Paxlovid for COVID-19 - 1 year(s) ago
‘Besides oxygen, Paxlovid has probably been the single most important treatment,’ says panelist
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
"Besides oxygen, #Paxlovid has probably been the single most important treatment tool in this epidemic." -- Richard Murphy, MD, MPH. https://t.co/29jmzezr1z @ingridhein @MedPageID
-
-
Mashup Score: 6
Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics.
Source: The LancetCategories: Expert Picks, Latest HeadlinesTweet-
PAXLOVID: And my fellow ID doctors, it is this same population (immunosuppressed, older) who need yearly #boosters in addition to #Paxlovid if infected in my opinion. This study tells us who is still at risk after 2 dose of vax https://t.co/d59GiAajp2 https://t.co/s0KtwwLw12
-
-
Mashup Score: 0Paxlovid Effectiveness Extends to New Omicron Subvariants - 1 year(s) ago
“Real-world” assessment finds nirmatrelvir-ritonavir reduces risk of severe COVID-19 from BA4 and BA5 omicron subvariants.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Paxlovid found as effective against #SARS-CoV-2 #BA4 and #BA5 as with earlier circulating #delta #omicron variants. https://t.co/uExtRGzoxr
-
-
Mashup Score: 3
Specifically for older individuals and immunocompromised individuals, a year could be too long.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet-
Specifically for older individuals and immunocompromised individuals, a year could be too long. https://t.co/HBfjh9Rhbr #COVID-19 #booster #novavax #APhA @CDCgov #ACIP #bivalent #monovalent #vaccine #molnupiravir #Paxlovid
-
-
Mashup Score: 0AES Clinical Corner - 1 year(s) ago
Clinical Corner features short-format video updates from experts on timely and important news and alerts in epilepsy. Clinical Corner AES Clinical Corner: Ganaxolone (Ztalmy®) This AES Clinical Corner video focuses on Ganaxolone (Ztalmy®), a medication approved by the FDA on March 18, 2022, for the treatment of seizures associated with cyclin-dependent…
Source: AESCategories: Latest Headlines, NeurologyTweet-
AES Clinical Corner features short-format video updates from experts on important news and alerts in #epilepsy. Learn more about #Ganaxolone and #Paxlovid in our last two videos, available here: https://t.co/B8T1A8C6I7
-
-
Mashup Score: 0
The findings offer clarity amid concerns that the use of Paxlovid increased the risk for COVID-19 rebound.
Source: MedscapeCategories: Cardiologists, Latest HeadlinesTweet-
#Paxlovid Doesn’t Increase Risk for Rebound #COVID Infection: Study https://t.co/8k2V90acWo via @medscape
-
-
Mashup Score: 1
Two new studies, one from the United States and one from Canada, suggest that the oral antiviral drug Paxlovid (nirmatrelvir-ritonavir) is effective in lowering the odds of hospitalization or death from the SARS-CoV-2 Omicron subvariant. Less clinically significant relapse Late last week in The Lancet Infectious Diseases, University of Colorado researchers used electronic health records to…
Source: CIDRAPCategories: Infectious Disease, Latest HeadlinesTweet-
#Paxlovid may help prevent hospitalization, death in #COVID19 outpatients The drug was linked to a reduced 28-day all-cause death rate and fewer emergency department visits for clinically significant relapse https://t.co/Yft9LN6N3a https://t.co/AAzfZNLu6f
-
-
Mashup Score: 0Paxlovid did not Reduce Mortality in Hospitalized COVID-19 Patients With Comorbidities - 1 year(s) ago
The antiviral did not modify SARS–CoV-2 RNA clearance, and did not increase the risk of adverse events.
Source: OncLiveCategories: Infectious Disease, Latest HeadlinesTweet-
In a new study, investigators wanted to see if there was therapeutic benefit to using #Paxlovid to treat hospitalized patients with the #Omicron variant. https://t.co/Pk7MRmeTP9
-
-
Mashup Score: 0Pharmalittle: Generic drugmakers may be helped by Inflation Reduction Act; Bayer union warns not to split the company - 1 year(s) ago
A German union opposes splitting up Bayer after the departure of its chief executive and warned the company should not bow to pressure from hedge fund activism.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Pharmalot.. Pharmalittle.. Good Morning: Generic drugmakers may be helped by Inflation Reduction Act; Bayer union warns not to split the company & More news.. https://t.co/im7eQIzrAO #pharma #COVID19 #Paxlovid #abortion #Medicare $NVO $BLUE $BAYRY $PFE
-
#SouthKorea researchers develop #AI to predict adverse drug reactions with Pfizer's #Paxlovid - The antiviral medication was found to interact with over 2,000 prescription drugs. https://t.co/MSjSMcgcZ7